Deb Kemper
Managing Director, Chair Emeritus, Boston Forum @ Golden Seeds
Boston, United States
Deb Kemper is a General Partner at Golden Seeds Venture Fund. She previously was the Boston Chair for Golden Seeds Angel Group. She is an active early-stage investor via Libra Global Partners, mentor to entrepreneurs, and board member. Prior to Golden Seeds, Deb was a management consultant at McKinsey & Company where she served clients inthe healthcare, energy, electronics and consumer products sectors. Deb earned an MBA from The Tuck School of Business at Dartmouth where she was a Tuck Scholar. She completed her BS in Engineering from Cornell University where she graduated With Distinction.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Deb Kemper invests in
Stages Deb Kemper invests in
Countries Deb Kemper invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- B2B 1 (50%)
- PaaS 1 (50%)
- SaaS 1 (50%)
- Internet 1 (50%)
- Software 1 (50%)
Stage
- Seed 1 (50%)
- Series A 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipelinespending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement. | $7M / Series A / Feb 06, 2024 | ||
| PerformLive is a purpose-driven community for Creators & Sellers to monetize their talent and products via interactive live stream. It combines the power of live interaction, augmented reality, social selling & live commerce, all in one platform. | $740.1K / Seed / Oct 30, 2020 |
Co-Investors
About Golden Seeds
Golden Seeds is a seed-stage investment firm with a focus on women leaders. Their investment thesis rests on the extensive research that concludes that gender-diverse teams produce a better return on equity. By seeking companies where women hold leadership positions and own substantial equity, they are funding companies that are likely to havediverse perspectives that will contribute to success.
Golden Seeds Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jo Ann Corkran
Managing Partner
|
|||
|
Ulya Khan
Managing Director
|
|||
|
Carolyn Fikke
Managing Director
|
|||
Charles Follini
Early Stage Investor & Board Member
|
|||
Danna Redmond
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Deb Kemper invest in?
Deb Kemper invests primarily in B2B, PaaS and SaaS startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Deb Kemper?
Public channels for Deb Kemper include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Deb Kemper last invest?
The most recent investment recorded for Deb Kemper closed in Feb 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
